Capital Fund Management (CFM)
NTLA icon

Capital Fund Management (CFM)’s Intellia Therapeutics NTLA Stock Holding History

Capital Fund Management (CFM)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.05M Sell
298,380
-431,742
-59% -$6.04M 0.02% 908
2026
Q1 		$9.36M Buy
730,122
+537,096
+278% +$6.84M 0.04% 580
2025
Q4 		$1.74M Buy
193,026
+2,628
+1% +$36.2K ﹤0.01% 1772
2025
Q3 		$3.29M Sell
190,398
-181,209
-49% -$2.23M 0.01% 1508
2025
Q2 		$3.49M Buy
371,607
+235,353
+173% +$1.93M 0.01% 1367
2025
Q1 		$969K Buy
+136,254
New +$1.38M ﹤0.01% 1680
2024
Q4 		– Sell
-18,705
Closed -$292K – 2186
2024
Q3 		$384K Buy
+18,705
New +$431K ﹤0.01% 1881
2024
Q2 		– Sell
-92,578
Closed -$2.2M – 2088
2024
Q1 		$2.55M Buy
+92,578
New +$2.57M 0.01% 1339
2023
Q2 		– Sell
-107,656
Closed -$4.01M – 1830
2023
Q1 		$4.01M Sell
107,656
-2,233
-2% -$87.6K 0.02% 807
2022
Q4 		$3.83M Buy
+109,889
New +$5.22M 0.03% 715

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Capital Fund Management (CFM)'s NTLA Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its Intellia Therapeutics (NTLA) stake by 59% in Q2 2026, selling an estimated $6.04M and leaving 298,380 shares worth $5.05M. The position accounts for 0.02% of the portfolio, ranked #908.

Capital Fund Management (CFM) first reported a position in NTLA in Q4 2022 and has held it in 10 quarters since. The position peaked at $9.36M in Q1 2026. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Capital Fund Management (CFM) held 298,380 shares of Intellia Therapeutics worth $5.05M as of Q2 2026.
  • Capital Fund Management (CFM) sold 431,742 Intellia Therapeutics shares in Q2 2026, an estimated $6.04M.
  • Intellia Therapeutics made up 0.02% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #908 holding.
  • Capital Fund Management (CFM) first reported a position in Intellia Therapeutics in Q4 2022 and has held it in 10 quarters since.
  • Capital Fund Management (CFM)'s Intellia Therapeutics position peaked at $9.36M in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.